Table 1.
Demographics in the persistence phase and booster phase.
| Characteristic | MenACWY-TT (Toddlers) n = 76 |
MenC-CRM n = 23 |
MenACWY-TT (Children) n = 115 |
MenACWY-PS n = 29 |
|---|---|---|---|---|
| Persistence phase* | ||||
| Age at enrollment (Study Year 6),† y | ||||
| Mean (SD) | 8.2 (0.7) | 8.2 (0.7) | 12.5 (2.6) | 12.1 (2.9) |
| Median (range) | 8.0 (7–10) | 8.0 (7–10) | 13.0 (8–18) | 12.0 (8–16) |
| Sex, n (%) | ||||
| Female | 40 (52.6) | 12 (52.2) | 56 (48.7) | 14 (48.3) |
| Male | 36 (47.4) | 11 (47.8) | 59 (51.3) | 15 (51.7) |
| White race, n (%) |
75 (98.7) |
22 (95.7) |
113 (98.3) |
28 (96.6) |
| Booster phase*‡ | ||||
| Age at enrollment (Year 6),§ y | ||||
| Mean (SD) | 8.2 (0.7) | 8.4 (0.8) | 12.0 (2.5) | 11.8 (2.9) |
| Median (range) | 8.0 (7–10) | 8.0 (7–10) | 12.0 (8–18) | 11.0 (8–16) |
| Sex, n (%) | ||||
| Female | 37 (55.2) | 8 (50.0) | 39 (50.6) | 9 (42.9) |
| Male | 30 (44.8) | 8 (50.0) | 38 (49.4) | 12 (57.1) |
| White race, n (%) | 66 (98.5) | 16 (100) | 77 (100) | 20 (95.2) |
*Date of birth, sex, and race were collected in the primary study.
†Age was computed based on the age at entry into the extension study.
‡All subjects received MenACWY-TT booster vaccine regardless of vaccine received in the primary study.
§Age is based on the age at entry into the extension study.